Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2464-2471

  Bruns, Anke H W ^a   Oosterheert, Jan Jelrik ^a   Kuijper, Ed J ^b   Lammers, Jan Willem J ^a   Thijsen, Steven ^c   Troelstra, Annet ^d   Hoepelman, Andy I M ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Colonization; Fluoroquinolones; Lower respiratory tract infections; Resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERYTHROMYCIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RIBOTYPING; RISK FACTOR; SKIN CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARRIER STATE; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PREVALENCE;

EID: 77957880644     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq329     Document Type: Article

References (31)

1. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
2. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
3. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
4. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80.
5. Hirschhorn LR, Trnka Y, Onderdonk A et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169: 127-33.
6. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
7. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
8. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162-70.
9. Drudy D, Harnedy N, Fanning S et al. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007; 28: 932-40.
10. Polgreen PM, Chen YY, Cavanaugh JE et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28: 212-4.
11. Saxton K, Baines SD, Freeman J et al. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009; 53: 412-20.
12. Zhanel GG, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13-59.
13. Chalmers JD, Al-Khairalla M, Short PM et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010; 65: 608-18.
14. Clabots CR, Johnson S, Olson MM et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992; 166: 561-7.
15. Muto CA. Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg? Clin Infect Dis 2007; 45: 999-1000.
16. Riggs MM, Sethi AK, Zabarsky TF et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45: 992-8.
17. Schouten JA, Prins JM, Bonten M et al. Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia. Ned Tijdschr Geneeskd 2005; 149: 2495-500.
18. McDonald LC, Coignard B, Dubberke E et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-5.
19. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-3.
20. Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 38: 2484-7.
21. Brazier JS, Raybould R, Patel B et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill 2008; 13:pi=19000.
22. Huang H, Weintraub A, Fang H et al. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009; 34: 516-22.
23. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth International Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
24. 50. J Antimicrob Chemother 1991; 27: 863-4.
25. Shim JK, Johnson S, Samore MH et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351: 633-6.
26. Kyne L, Warny M, Qamar A et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-7.
27. Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect 2001; 7: 411-6.
28. McFarland LV, Clarridge JE, Beneda HW et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007; 45: 1141-51.
29. Gerding DN. New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile. Infect Control Hosp Epidemiol 2007; 28: 113-5.
30. Rivera EV, Woods S. Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med 2003; 6: 27-30.
31. Owens RC. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 2007; 67: 487-502.